Product Detail


Share to:
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Cas No. 2189684-53-3, 1H-Indazol-3-amine, 4-chloro-7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-(2,2,2-trifluoroethyl)-

  • 2189684-53-3

  • C15H18BClF3N3O2

  • 375.58

  • 1.39±0.1

  • 98%min

  • Anti-HIV

  • Lenacapavir

  • 8/16/2038 (Lenacapavir)

  • capsid

  • N

  • ISO 9001;ISO 14001;ISO 45001; GMP



Delivering a novel approach through long-acting injections, Lenacapavir offers extended therapeutic coverage, transforming patients' lives by reducing treatment regimen burden. Its potent antiviral activity against drug-resistant strains empowers your company to tackle the evolving challenges of HIV. With its favorable safety profile and potential for improved adherence, Lenacapavir opens new doors for enhanced patient care and reinforces your commitment to combatting HIV. Embrace this revolutionary medication to forge a brighter future for those affected by the virus.

ROS and Usage

We are pleased to introduce CAS RN 2189684-53-3, a critical intermediate in the Lenacapavir synthesis process. This vital compound is a part of Unibest's commitment to equipping our customers with efficient and high-quality solutions for pharmaceutical production.

Usage: CAS RN 2189684-57-7 Synthesis

Notably, CAS RN 2189684-53-3 proves critical to the synthesis of CAS RN 2189684-57-7. Together with our product CAS RN 2189684-54-4, these intermediates facilitate the creation of CAS RN 2189684-57-7, leading to a smoother production process for the final Lenacapavir API.

2189684-53-3 and 2189684-54-4 in Lenacapavir Synthesis

Embrace Unibest's innovative and efficient solutions to meet your pharmaceutical manufacturing needs. Our comprehensive range of high-value pharmaceutical intermediates and active pharmaceutical ingredients empowers your endeavors in the demanding pharmaceutical industry.